Updated guidelines favor cholesterol drugs for more US adults
The 2026 framework identified 15.9 million more untreated US adults for consideration of cholesterol-lowering medication than the 2018 framework.
Our read
Industry & policy- Studied:
- Cross-sectional study of 6,118 U.S. adults aged 40-75 years, against adults under the 2018 framework
- What changed:
- The number of untreated adults considered for cholesterol-lowering medication rose by 15.9 million under the updated versus older guideline
- The catch:
- Treatment classifications excluded refinement using coronary artery calcium or additional risk factors
Editor of record: Boris Djordjevic · AgingResearch.News
US adults aged 40–75 provided data for an observational analysis comparing the 2018 and 2026 American College of Cardiology and American Heart Association cholesterol guidelines. The 6,118 participants came from the 2013–2023 National Health and Nutrition Examination Survey. Survey-weighted estimates represented 118.9 million adults.
Among the estimated 82.9 million adults not taking cholesterol-lowering medication, the group recommended medication grew from 21.2 million (25.6%) under the older framework to 31.2 million (37.7%) under the newer one. Everyone recommended medication under the older guideline remained in that category. The researchers assigned categories using cholesterol levels, health conditions and calculated risk scores.
Why it matters
Cholesterol care in middle and later adulthood depends partly on treatment thresholds. Estimating who crosses those thresholds can help anticipate the reach of guideline-based prevention.
Caveats
The analysis estimated recommendation categories, not health benefits or harms. The classifications preceded further individualized assessment using calcium in heart arteries or additional risk factors.
- 2026 dyslipidemia guideline
- Dyslipidemia
- LDL cholesterol
- Pooled-cohort equation risk score
- PREVENT risk score
- Humans
The paper
Albert Einstein College of Medicine; Yale University
AHA Scientific Sessions 2026 Abstract, Nov 2, 2026
Presented at AHA Scientific Sessions 2026, abstract 9877
Comments
Be the first to comment.